NovaBridge Biosciences Unveils New Identity and Strategic Direction
I'm PortAI, I can summarize articles.
I-MAB has rebranded as NovaBridge Biosciences, with shareholders approving the name change on October 24, 2025. The new ticker symbol 'NBP' will be used starting October 30, 2025. This strategic shift aims to enhance capital access and innovation through a dual listing on Nasdaq and the Hong Kong Stock Exchange. The company has launched a subsidiary, Visara, Inc., for ophthalmic therapeutics and is advancing clinical trials for its core assets. Analyst ratings reflect a cautious outlook due to financial challenges, with a recent Buy rating and a $7.00 price target for the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments